Samantha McClellan
she/her/hers
Research
Publications
2026
STIM1 and endoplasmic reticulum–plasma membrane contact sites oscillate independently of calcium-induced calcium release
Xiong D, Tong C, Fung S, McClellan S, Yang Y, Yong J, Wu M. STIM1 and endoplasmic reticulum–plasma membrane contact sites oscillate independently of calcium-induced calcium release. Open Biology 2026, 16: 250220. PMID: 41844235, DOI: 10.1098/rsob.250220.Peer-Reviewed Original ResearchThis study investigates how STIM1 and ER-plasma membrane contact sites oscillate independently of calcium signaling, revealing a new mechanism regulating calcium dynamics in cells.
2025
Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia
Pham-Danis C, Novak A, Danis E, McClellan S, Leach L, Yarnell M, Ebmeier C, Tasian S, Kohler M. Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia. Cancer Cell 2025, 43: 482-502.e9. PMID: 40068599, PMCID: PMC12002840, DOI: 10.1016/j.ccell.2025.02.008.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAnimalsCell Line, TumorCell ProliferationHumansImmunotherapy, AdoptiveLymphocyte ActivationMembrane ProteinsMicePhosphorylationPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 2Signal TransductionT-LymphocytesXenograft Model Antitumor AssaysConceptsChimeric antigen receptorCAR-T cellsT cellsCAR-TSecond-generation CARSecond-generation CAR-T cellsCAR-T cell therapyActivation of T cellsT-cell therapyT-cell sensitizationAcute lymphoblastic leukemiaLong-term efficacyMultiple mechanismsRelapsed/refractory leukemiaAP-1 activityIntracellular domainLymphoblastic leukemiaAntigen receptorCell therapyCell sensitivityLeukemiaLAT phosphorylationAP-1RelapseMAPK signaling
2024
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia
Balestra T, Niswander L, Bagashev A, Loftus J, Ross S, Chen R, McClellan S, Junco J, Bárcenas López D, Rabin K, Fry T, Tasian S. Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia 2024, 39: 555-567. PMID: 39681640, PMCID: PMC11879877, DOI: 10.1038/s41375-024-02493-3.Peer-Reviewed Original ResearchConceptsChimeric antigen receptor T cellsPatient-derived xenograftsPh-likeDS-ALLPreclinical activityLymphoblastic leukemiaB-acute lymphoblastic leukemiaThymic stromal lymphopoietin receptorCD19 antigen lossRelapsed/refractory B-ALLT cell proliferationAcute lymphoblastic leukemiaJAK1/2 inhibitor ruxolitinibALL cell linesIn vivoRelapse preventionProliferation in vitroImmunotherapeutic resistanceCellular immunotherapyLeukemia relapsePDX miceCRLF2 rearrangementsRemission rateAntigen lossB-ALL